AI Article Synopsis
- The study evaluated the effectiveness of CT-guided (125)I brachytherapy for treating metastatic lymph nodes in patients with primary hepatic carcinoma (PHC).
- Twenty patients were treated using a computerized treatment planning system to ensure precise placement of radioactive seeds, monitored through CT scans.
- Results showed a decreasing local control rate over time, with no severe complications reported, indicating that this method is both effective and safe for patients.
Article Abstract
Objective: To discuss the clinical value of CT-guided (125)I brachytherapy with retroperitoneal metastatic lymph nodes from primary hepatic carcinoma(PHC).
Methods: Twenty patients with retroperitoneal metastatic lymph node recurrence from PHC were percutaneously treated by (125)I brachytherapy with computed tomographic (CT) guidance. The number, radioactive dose, placed position of radioactive seeds and puncture path were determined by computerized treatment planning system (TPS). The radioactive seeds were implanted when the needles were in right position by CT scan. Radiotherapy verification and quality assessment were performed after treatment by CT scan. Follow-up contrast material-enhanced CT were reviewed.
Results: The local control rate of 3, 6, 10, 15 months was 70.0%, 56.3%, 44.4%, 25.0% respectively. There were no severe complications such as massive bleeding and radiation injury of normal tissues.
Conclusion: CT-guided (125)I brachytherapy are effective and may be safely applied to retroperitoneal metastatic lymph nodes from PHC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ultrasound and CT-guided implantation of iodine-125 seeds combined with transarterial chemoembolization for recurrent hepatocellular carcinoma at complex sites after hepatectomy.
Brachytherapy
January 2025
Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China. Electronic address:
Objective: The objective of this study was to evaluate the efficacy and safety of TACE combined with 125I seeds (TACE-125I) in the treatment of recurrent HCC at complex sites after hepatectomy.
Methods: This study retrospectively analyzed the clinical data of recurrent HCC patients located at complex sites (such as large blood vessels, diaphragm dome, etc.) after hepatectomy from January 2012 to December 2023, all of whom received TACE-125I or TACE therapy.
EBUS-guided Iodine-125 seed implantation in lymph node as a novel therapy for MCAO: A case report.
Medicine (Baltimore)
January 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Rationale: We report here a case of using iodine-125 (125I) seed implantation via endobronchial ultrasound (EBUS) in the treatment of malignant central airway obstruction (MCAO) in a patient with lung adenocarcinoma.
Patient Concerns: The patient still experienced MCAO after conventional bronchoscopic interventional therapy.
Diagnoses: The patient was diagnosed as lung adenocarcinoma stage IV (T4N2M1a).
Integrated transcriptomics and proteomics analysis of the impact of iodine‑125 in hepatocellular carcinoma.
Mol Med Rep
March 2025
The First Central Clinical School, Tianjin Medical University, Tianjin 300000, P.R. China.
Hepatocellular carcinoma (HCC) is a common cause of cancer‑related mortality and morbidity worldwide. While iodine‑125 (I) particle brachytherapy has been extensively used in the clinical treatment of various types of cancer, the precise mechanism underlying its effectiveness in treating HCC remains unclear. In the present study, MHCC‑97H cells were treated with I, after which, cell viability and proliferation were assessed using Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine and colony formation assays, cell invasion and migration were evaluated using wound healing and Transwell assays, and cell apoptosis was determined using flow cytometry.
View Article and Find Full Text PDFUltra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Article Synopsis
- The study retrospectively evaluated the effectiveness of ultra-low dose rate brachytherapy (uLDR-BT) in 39 patients with unfavorable intermediate risk prostate cancer, despite current guidelines recommending against it due to insufficient evidence.
- Results showed a promising median follow-up of about 56 months, with an 87.02% biochemical failure-free survival rate, indicating uLDR-BT could be a viable treatment option.
- No significant differences in outcomes were observed based on additional risk factors or treatment methods, suggesting that uLDR-BT's effectiveness is consistent across different patient profiles in the intermediate risk category.
Sensitivity of contributing factors to heterogeneity corrections in dosimetry of ocular brachytherapy using iodine-125 COMS plaques.
J Contemp Brachytherapy
October 2024
Department of Radiation Oncology, East Carolina University, Greenville, North Carolina, USA.
Purpose: To investigate sensitivity of contributing factors to heterogeneity corrections in ocular brachytherapy using iodine-125 (I) Collaborative Ocular Melanoma Study (COMS) plaques.
Material And Methods: Using egs_brachy, Monte Carlo (MC) simulations were performed for I COMS plaques (model: IsoAid IAI-125A). Homogeneous dose (D) was estimated under the American Association of Physicists in Medicine Task Group-43 assumptions, with 85 Gy prescribed to a 5 mm depth.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!